Transcriptional Co-repressor Function of the Hippo Pathway Transducers YAP and TAZ  by Kim, Minchul et al.
ArticleTranscriptional Co-repressor Function of the Hippo
Pathway Transducers YAP and TAZGraphical AbstractHighlightsd YAP/TAZ function as transcriptional co-repressors
d TEAD is required for target gene repression by YAP/TAZ
d The NuRD complex mediates repression of DDIT4 and Trail
by YAP/TAZ-TEAD
d YAP/TAZ promote cell growth and survival by repressing
DDIT4 and TrailKim et al., 2015, Cell Reports 11, 270–282
April 14, 2015 ª2015 The Authors
http://dx.doi.org/10.1016/j.celrep.2015.03.015Authors
Minchul Kim, Taekhoon Kim, Randy L.
Johnson, Dae-Sik Lim
Correspondence
merchikim@kaist.ac.kr (M.K.),
daesiklim@kaist.ac.kr (D.-S.L.)
In Brief
YAP and TAZ are known as oncogenic
transcriptional co-activators and key
regulators of stem cell function. Here, Kim
et al. show that YAP and TAZ can also
function as transcriptional co-repressors
to promote cell growth and survival,
providing a new perspective for
understanding the downstream outcome
of YAP/TAZ activation.Accession NumbersGSE60579
Cell Reports
ArticleTranscriptional Co-repressor Function of the
Hippo Pathway Transducers YAP and TAZ
Minchul Kim,1,* Taekhoon Kim,1 Randy L. Johnson,2 and Dae-Sik Lim1,*
1National Creative Research Center for Cell Division and Differentiation, Department of Biological Sciences, Korea Advanced Institute of
Science and Technology (KAIST), Daejeon 305-701, Korea
2Department of Cancer Biology, University of Texas, M.D. Anderson Cancer Center, Houston, TX 77030, USA
*Correspondence: merchikim@kaist.ac.kr (M.K.), daesiklim@kaist.ac.kr (D.-S.L.)
http://dx.doi.org/10.1016/j.celrep.2015.03.015
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARY
YAP (yes-associated protein) and TAZ are oncogenic
transcriptional co-activators downstream of the Hip-
po tumor-suppressor pathway. However, whether
YAP and/or TAZ (YAP/TAZ) engage in transcriptional
co-repression remains relatively unexplored. Here,
we directly demonstrated that YAP/TAZ represses
numerous target genes, including tumor-suppressor
genes such as DDIT4 (DNA-damage-inducible tran-
script 4) and Trail (TNF-related apoptosis-inducing
ligand). Mechanistically, the repressor function of
YAP/TAZ requires TEAD (TEA domain) transcription
factors. A YAP/TAZ-TEAD complex recruits the
NuRD complex to deacetylate histones and alters
nucleosome occupancy at target genes. Function-
ally, repression of DDIT4 and Trail by YAP/TAZ is
required for mTORC1 (mechanistic target of rapamy-
cin complex 1) activation and cell survival, respec-
tively. Our demonstration of the transcriptional co-
repressor activity of YAP/TAZ opens a new avenue
for understanding the Hippo signaling pathway.INTRODUCTION
YAP (yes-associated protein) and TAZ are potent oncogenic
transcriptional co-activators that are opposed by the Hippo tu-
mor-suppressor pathway. YAP is amplified in multiple forms of
human cancers (Harvey et al., 2013). Overexpression of YAP
and/or TAZ (YAP/TAZ) in normal epithelial cells induces cell
transformation and confers a cancer stem cell phenotype (Cor-
denonsi et al., 2011; Overholtzer et al., 2006). Furthermore,
YAP overexpression promotes hyperproliferation of tissue
stem/progenitor cells and leads to cancer development in multi-
ple epithelial tissues in mice (Camargo et al., 2007). YAP is
crucial for cancer development induced by an Lkb1 deficiency,
b-catenin activation, or oncogenic Ras mutation (Kapoor et al.,
2014; Mohseni et al., 2014; Rosenbluh et al., 2012; Shao et al.,
2014). Thus, one of the most important issues in the field is to
identify target genes of YAP/TAZ that mediate their oncogenic
activity. Since YAP/TAZ are regarded as transcriptional co-acti-270 Cell Reports 11, 270–282, April 14, 2015 ª2015 The Authorsvators, many studies to date have focused on identifying genes
upregulated by YAP/TAZ; several target genes, including CTGF
(connective tissue growth factor), have been found (Zhao et al.,
2008).While these genes explain some facets of the YAP overex-
pression phenotype, they do not fully account for YAP/TAZ func-
tion, suggesting that additional target genes remain to be
discovered. An alternative explanation would be that YAP/TAZ
repress expression of genes that inhibit cell growth or induce
cell death. However, repressor functions of YAP/TAZ have
been poorly investigated, with a single study suggesting that
YAP/TAZ repress the expression ofmesendoderm lineage genes
in human embryonic stem (ES) cells (Beyer et al., 2013). Here, we
have directly addressed whether YAP/TAZ can function as tran-
scriptional co-repressors, demonstrating that they can function
as oncogenes by repressing antiproliferative and cell-death-
inducing genes.RESULTS
YAP/TAZ Function as Transcriptional Co-repressors
To identify immediate target genes of YAP, we established an
inducible system by fusing ERT2 (ligand binding domain of the
estrogen receptor) to the N terminus of a constitutively active
YAP S127/381A (YAP 2SA)mutant (Zhao et al., 2009) (Figure 1A).
ERT2-fused proteins are normally inactive, but upon treatment
with 4-OHT (4-hydroxytamoxifen), they rapidly translocate to
the nucleus. ERT2-YAP 2SA was stably expressed in MCF10A
cells followed by treatment with 4-OHT for 2 and 6 hr. As a con-
trol, we used 4-OHT-treated MCF10A cells expressing ERT2
only. ERT2-YAP 2SA had accumulated in the nucleus by 2 hr
after 4-OHT treatment, as judged by both immunofluorescence
and cell fractionation experiments (Figures S1A and S1B).
ERT2-YAP 2SA was functionally active, as 4-OHT treatment
robustly induced CTGF and Cyr61, which are two well-estab-
lished targets of YAP (Figures S1C and S1D). Notably, ERT2-
YAP 2SA was markedly stabilized by 6-hr post-treatment with
4-OHT (lane 6; Figure S1C).
Microarray analyses revealed that 100 genes were acutely
suppressed (>2-fold) following 4-OHT treatment in ERT2-YAP
2SA cells (Figure 1B; Table S1). Interestingly, these downregu-
lated genes included some tumor suppressor genes, such as
DDIT4 (DNA-damage-inducible transcript 4), Trail (TNF-related
apoptosis-inducing ligand), andTSC22D (TGFb-stimulated clone
22 domain) transcripts. Notably, many angiogenic genes and
epithelial sodium channel subunits (ENaC complex) were also
repressed by YAP, although the biological significance of these
phenomena is not yet clear. The number of identified YAP-
repressed genes shown in Figure 1B may be an underestimate,
since it depends on the degradation kinetics of pre-existing
transcripts. As expected, numerous genes were also activated
following 4-OHT treatment (Table S2). A detailed Gene Ontology
analysis of these activated genes will be reported elsewhere
(T.K. et al., unpublished data). Among the 85 genes that were
activated >2-fold, 46 and 25 were previously reported to be
increasedmore than 2-fold in YAP overexpressingMCF10A cells
(Zhao et al., 2008) and mouse liver cells (Dong et al., 2007),
respectively (indicated in Table S2). The nonoverlapping genes
might reflect the use of different YAP constructs (ERT2-YAP
2SA versus YAP WT) or different cell types. This lack of overlap
could also be also due to differences in the induction kinetics
of the various target genes, given that our analysis is likely to
capture early activated genes rather than latently activated
genes.
To validate the repressed target genes, we performed quanti-
tative RT-PCR (RT-qPCR) against seven selected target genes
and found that all seven transcripts were repressed following
4-OHT treatment (Figure S1D). Two of them (DDIT4 and Trail)
were also validated at the protein level (Figure S1C). We then
refined our experimental system by using the YAP 5SA mutant,
in which all five LATS1/2 target sites are mutated. This mutant
was chosen because it is more active and has been widely
used for functional studies of YAP. Again, induction of YAP activ-
ity by incubating with 4-OHT for 12 hr led to a reduction in
the expression of selected target genes, as determined by RT-
qPCR (Figure 1C). Conversely, depletion of YAP/TAZ strongly
upregulated the selected target genes (Figure 1D). Interestingly,
depletion of TAZ alone had a weaker effect on target gene dere-
pression than did YAPdepletion alone.We also found that deple-
tion of Dicer1, an essential enzyme in miRNA processing, had no
effect on the target gene repression induced by ERT2-YAP 5SA
(Figures S1E and S1F). This result excludes the possibility that
YAP/TAZ indirectly repress these target genes by inducing
miRNA expression. Notably, Trail and CA12 (carbonic anhydrase
XII) were significantly repressed even before 4-OHT treatment
(Figure 1C), possibly because of ‘‘leaky’’ activity of ERT2-YAP
5SA. Consistent with this, Trail and CA12 were the most strongly
derepressed genes upon YAP/TAZ depletion (Figure 1D). West-
ern blotting confirmed that YAP 5SA overexpression reduced
DDIT4 and Trail at the protein level (Figure 1E), whereas deple-
tion of YAP/TAZ increased both proteins (Figure 1F). Expression
of YAP 5SA in human retinal epithelial (RPE) cells or AML12 cells
(murine hepatocytes) also decreased DDIT4 and Trail protein
expression (Figure S2), indicating that the repressor function of
YAP is not restricted to breast epithelial cells. To determine if
YAP/TAZ execute a repressor function in a cancer context, we
restored human SAV1 (salvador family WW domain-containing
protein 1) expression in a cell line isolated from liver cancer
developed in a Sav1/p53 liver conditional knockout (cKO)
mouse. Restoration of human SAV1 activated Lats1/2 (large
tumor suppressor kinase-1/2), as evidenced by increased
Lats1/2 phosphorylation, in association with increased YapS127 phosphorylation. CTGF was reduced, whereas DDIT4
and Trail were increased (Figure 1G).
Repression by YAP/TAZ Requires TEAD Transcription
Factors
To dissect the YAP/TAZ repressor complex, we expressed
several mutant forms of YAP. A S94Amutation, which abrogates
the interaction with TEAD (TEA domain) transcription factors
(Zhao et al., 2008), largely abolished the repressor activity of
YAP 5SA (Figures 2A and 2B). In line with this, depletion of
TEAD1/3/4 restored DDIT4 and Trail expression in YAP 5SA-ex-
pressing cells (Figure 2C). TEAD transcription factors are essen-
tial for the transcriptional co-activator function of YAP/TAZ;
hence, it was unexpected that TEAD was also involved in their
co-repressor function. Deletion of the WW domain in YAP 5SA
also compromised repressor activity against some target genes,
although the effect varied greatly among target genes (Figures
2A and 2B). We also examined the effect of an Y357F mutation
on the repressor activity of YAP 5SA. Y357 phosphorylation by
c-Abl or c-Yes has been proposed to affect target gene choice
(Levy et al., 2008; Rosenbluh et al., 2012). However, we found
no effect of the Y357F mutation on the repressor activity of
YAP (Figures 2A and 2B). To examine TEAD andWWdomain de-
pendency globally, we reanalyzed previously published microar-
ray data obtained in MCF10A cells stably expressing WT YAP
(YAP WT), YAP S94A, or YAP DWW (Zhao et al., 2008). Among
the downregulated genes in YAP WT-expressing cells, nearly
80% were dependent on either the TEAD-binding domain or
the WW domain (Figure 2D). We conclude that the repressor
activity of YAP is largely dependent on the TEAD transcription
factor, but the WW domain of YAP also plays a role in repressing
a subset of target genes.
YAP/TAZ Directly Bind to DDIT4 and Trail Genes
We next tested whether YAP/TAZ-TEAD directly repressed
expression of DDIT4 and Trail by binding to genomic DNA. To
do this, we first surveyed the genome sequence of the Trail
gene, noting the presence of four putative TEAD-binding se-
quences (CATTCC) around the transcription start site (TSS) (Fig-
ure 2E). In Trail gene, three motifs were located in the promoter,
and onewas found 3.75-kb downstream of TSS. DDIT4 is a small
gene, encompassing only about 3 kb. In contrast to Trail, we did
not find a CATTCC motif in the DDIT4 gene. However, in vitro
binding studies and several case studies reported that, whereas
mutations within the first three bases in the TEAD-binding motif
are extremely detrimental to TEAD binding, a single nucleotide
change within the last three bases is tolerated (Larkin et al.,
1996; Stewart et al., 1994). Thus, we searched for these variant
binding motifs and found two such regions in DDIT4 (Figure 2E).
Chromatin immunoprecipitation (ChIP) assays using an anti-Flag
antibody in Flag-YAP 5SA-expressing cells showed enrichment
of YAP near the TSS in both DDIT4 and Trail (Figure 2F). Consis-
tent with the idea that TEAD recruits YAP to the repressed target
genes, depletion of TEAD1/3/4 abrogated the enrichment of YAP
at these target genes (Figure 2G). We also surveyed the ge-
nomes of other species and found that the TEAD binding motifs
of DDIT4 and Trail are conserved in primates, canine, and ro-
dents (Figure S3A), but not in zebrafish, chicken, or Drosophila.Cell Reports 11, 270–282, April 14, 2015 ª2015 The Authors 271
Figure 1. YAP/TAZ Function as Transcriptional Co-repressors
(A) Cartoon depicting the ERT2-YAP system.
(B) Heat map of target genes repressed upon ERT2-YAP activation. Each block represents transcript levels in 4-OHT-treated ERT2-YAP 2SA cells normalized to
that in control cells. Shown below is the scale of the heat map.
(C) MCF10A cells transduced with ERT2-YAP 5SA or ERT2 only (control) were treated with vehicle or 4-OHT for 12 hr. mRNA levels of the indicated target genes
(normalized to b-actin) were quantified by RT-qPCR. Error bars indicate the SEM (n = 3).
(D) MCF10A cells were transfected with siRNA against YAP, TAZ, or both. mRNA levels of target genes were quantified as in (C). Error bars indicate the SEM
(n = 5).
(legend continued on next page)
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To test whether the conserved TEAD bindingmotifs in themouse
genome are functional, we examined Flag-YAP 5SA enrichment
in AML12 cells. Indeed, Flag-YAP 5SA was found to be enriched
at the predicted TEAD binding motifs, but not at negative control
regions (Figure S3B).
YAP Represses Reporter Activity Driven by the Trail
Promoter
To further demonstrate that DDIT4 and Trail are directly
repressed target genes of YAP, we next designed reporter as-
says. We cloned the promoter region of DDIT4 spanning from
1 kb to right before the second exon (the TEAD binding motif
is located in the first exon) and inserted it upstream of the lucif-
erase gene.We also cloned the promoter region of Trail spanning
from 2 kb to +200 bp and inserted it upstream of the luciferase
gene. The DDIT reporter construct proved to be unresponsive to
YAP (data not shown), suggesting that more genomic elements
are required. In contrast, Trail reporter activity was efficiently
repressed in YAP 5SA-expressing MCF10A cells (column 1, Fig-
ure 3B). Importantly, MCF10A cells expressing the YAP 5SA/
S94A mutant failed to repress this reporter, validating the
requirement of TEAD (column 2, Figure 3B). We performed sub-
sequent mutagenesis studies using this Trail reporter as a tem-
plate. As expected, the CTGF promoter reporter (500 bp to
the TSS) was activated in YAP 5SA-expressing cells, but not in
YAP 5SA/S94A-expressing cells (Figure 3B, right graph).
Figure 3A depicts all the Trail reporter constructs used in this
study. When one of the two TEAD binding motifs was disrupted,
YAP 5SA still repressed the activity of the reporter (columns 3
and 4, Figure 3B). In contrast, the disruption of both sites largely
abolished this repressive effect (column 5, Figure 3B), indicating
that both sites contribute to Trail repression. Because the YAP/
TAZ-TEAD complex is involved in both gene activation and
repression, we questioned what factors might determine the
outcome in this system. One possibility would be the genomic
landscape surrounding the TEAD binding site. Another would
be the strength of TEAD binding itself, with (for example) strong
TEAD binding tending toward activation while low to modest
bindingmight tend toward repression. To test these possibilities,
we substituted the TEAD bindingmotifs in the Trail promoter with
that found in the strongly activated target gene, CTGF. If the acti-
vation/repression choice is governed by the TEAD binding affin-
ity, then one would expect that the substituted reporter would
act as an activator.
The CTGF promoter contains three CTGF binding motifs; the
latter two motifs are clustered together, separated by only
3 bp, while the first is 60 bp away from the second. Mutation of
one of the latter two motifs was reported to decrease the
CTGF promoter reporter activity more strongly than mutation
of the first motif (Zhao et al., 2008). In addition, TEAD was shown
to strongly bind to DNA having two TEAD binding motifs with
3-bp spacing (Jiang et al., 2000). Thus, we herein substituted(E) Lysates from MCF10A cells transduced with Flag-YAP 5SA or empty (control
(F) Western blot analysis of lysates from MCF10A cells transfected with YAP/TA
(G) Control or human SAV1 retroviruses were infected to Sav1/p53 deficient prim
YAP phosphorylation, and target genes by western blotting. An asterisk (*) indicat
values (paired Student’s t test).the two TEAD binding motifs of Trail with latter two TEAD binding
motifs of CTGF (GGAATGcgaGGAATG).
Our results revealed that reporters with individual or com-
pound substitutions did not switch to having activator functions;
they were still repressed by YAP 5SA, but not by the S94A
mutant (columns 6–11, Figure 3B). The fold repression triggered
by YAP 5SA was decreased by these substitutions, but not to a
statistically significant degree. As shown in Figure 3B, although
the presence of a high-affinity TEAD binding motif (substitution
with the TEAD motifs of CTGF) tended to slightly enhance
gene expression, it failed to fully activate the downstream gene
if placed within repression-promoting DNA sequences. Based
on these results, we propose that the intrinsic strength of the
TEAD binding motif and the surrounding genomic landscape
both contribute to downstream gene expression.
YAP/TAZ Induce Epigenetic Changes at DDIT4
and Trail Loci
To explore epigenetic mechanisms underlying repression, we
first investigated recruitment of RNA polymerase (Pol2). Tran-
scriptional silencing can be accomplished by inhibition of either
transcription initiation or elongation. Pol2 occupancy was signif-
icantly reduced at both promoter and gene body regions of
DDIT4 and Trail loci in YAP 5SA-expressing cells (Figure 4A,
left two panels). Conversely, YAP/TAZ depletion markedly in-
creased Pol2 recruitment to both promoter and gene body re-
gions (Figure 4A, right two panels). These results suggest that
YAP/TAZ inhibit transcription initiation rather than elongation.
We then surveyed major histone modifications. We consid-
ered the possibility that YAP/TAZ induce heterochromatin struc-
tures marked by H3K9me3, H4K20me3, or H3K27me3. ChIP
assays using antibodies against H3K9me3 or H4K20me3 at the
Trail locus showed that these markers were not affected by
YAP overexpression or YAP/TAZ depletion (Figures S4A and
S4B). YAP/TAZ depletion also did not affect these modifications
at the DDIT4 locus (Figures S4A and S4B). Intriguingly, these
modifications were reduced at the DDIT4 locus upon YAP 5SA
overexpression (Figures S4A and S4B). We speculate that
H3K9/H4K20 are not efficiently methylated at the DDIT4 locus,
such that it cannot catch up with the increase in total histone
occupancy following the expression of YAP 5SA (see below).
Critically, these changes cannot account for the observed
YAP-mediated repression on DDIT4. H3K27 methylation is
executed by polycomb complex 2 (PRC2), in which EZH2
(enhancer of zeste 2 polycomb repressive complex 2 subunit)
is the catalytic subunit (Cao et al., 2002). The PRC1 complex,
which includes the polycomb ring finger oncogene Bmi1, coop-
erates with PRC2 to repress target genes. However, depletion of
either EZH2 or Bmi1 had no effect on the repressor activity of
YAP 5SA (Figures S4C and S4D).
On the other hand, H3K4me3 and H3K79me2, markers of
active transcription, were reduced in cells expressing YAP 5SA,) retroviruses were analyzed for the indicated proteins by western blotting.
Z or control siRNA. S.E., short exposure; L.E., long exposure.
ary liver cancer cells. Cell lysates were analyzed for Lats1/2 phosphorylation,
es a nonspecific signal. For (C) and (D), the numbers above the bars indicate p
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Figure 2. TEAD Is Required for YAP/TAZ-Mediated Target Gene Repression
(A) MCF10A cells were transduced with the indicated YAP mutants. Selected cells were analyzed by RT-qPCR for the indicated target genes. Error bars indicate
the SEM (n = 4).
(B) Samples from (A) were analyzed by western blotting.
(C) YAP 5SA-expressing or control MCF10A cells were transfected with siRNA against TEAD1/3/4. Note that TEAD4 is also a YAP target gene.
(D) MCF10A microarrays from Zhao et al. (2008) (GEO: GSE13218) were reanalyzed. A gene was considered to be repressed by YAP WT if the log2 value was
decreased by more than 1. Such genes were regarded as either TEAD- or WW domain-dependent if log2(S94A or DWW) – log2(WT) was greater than 0.5.
(E) Schematic diagram showing the DDIT4 and Trail locus in the vicinity of the TSS. Amplicons at the TEAD-binding motifs are indicated as red lines. Numbers
refer to nucleotide positions with respect to the TSS. Transcription proceeds from left to right. Boxes indicate exons, with black indicating coding regions and
white indicating untranslated regions. The drawing is not to scale.
(F) MCF10A cells expressing Flag-YAP 5SA, or vector-transduced control cells, were subjected to ChIP using anti-Flag or IgG (control) antibody. Precipitated
DNA was analyzed by qPCR using the amplicons indicated in (E) and normalized as percent of input; 1.9 kb of DDIT4 and 13.5 kb of Trail were used as internal
negative controls. Data were normalized by adjusting the Flag enrichment of control cells to 1. Error bars indicate the SEM (n = 4 for DDIT4 and n = 5 for Trail).
(G) TEAD1/3/4 was knocked down by siRNA in Flag-YAP 5SA-expressing cells. Flag ChIP samples were analyzed by qPCR using the indicated amplicons. Error
bars indicate the SEM (n = 4).
For (A), (F), and (G), the numbers above the bars indicate p values (paired Student’s t test).but were increased in cells depleted of YAP/TAZ (Figures S4E
and S4F). However, these modifications are coupled with active
transcription and thus are likely a reflection of reduced gene ac-
tivity. Histone acetylation, regardless of target lysine residue, is274 Cell Reports 11, 270–282, April 14, 2015 ª2015 The Authorsgenerally associated with gene activation. ChIP-qPCR assays
using a pan-acetylated H3 antibody indicated that H3 acetylation
was reduced by YAP 5SA expression (Figure 4B, left two col-
umns), but increased by YAP/TAZ depletion (Figure 4B, right
Figure 3. YAP Represses Trail Promoter-Driven Reporter Activity
(A) The Trail reporter constructs used in this study. The TEAD binding motifs and their positions with respect to the TSS are indicated in red. The numbers in
parentheses refer to the positions of the last base of each TEAD binding motif. CTGF sequence refers to GGAATGcgaGGAATG.
(B) (Left) MCF10A cells were transduced with vector (control), Flag-YAP 5SA, or Flag-YAP 5SA/S94A retroviruses and then transfected with the indicated reporter
constructs and CMV-Renilla. Reporter activity was measured 1 day after transfection and normalized with respect to the Renilla luciferase signal. For each
reporter construct, the reporter activity in YAP 5SA or YAP 5SA/S94A cells was divided by that in control cells. (Right) A CTGF promoter (500 bp to the TSS)-
driven luciferase reporter was transfected to each cell line, and luciferase signals were quantified as described above. Error bars indicate the SEM (n = 5), and the
numbers above the bars indicate p values (paired Student’s t test).two columns). While performing systematic analyses of histone
modifications usingChIP, we noticed that the total amount of his-
tone near the TSSwas strongly affected byYAP/TAZ,withH3 oc-
cupancy increased by YAP 5SA expression and decreased by
YAP/TAZ depletion (Figure 4C). It is thought that promoters are
depleted of nucleosomes to allow binding of transcription fac-
tors. Thus, the increased histone occupancy could exert inhibi-
tory effects on gene activation. On the basis of these results,
we propose that the YAP/TEAD complex affects histone acetyla-
tion and occupancy at the promoter of DDIT4 and Trail genes.
The NuRD Complex Mediates the Repressor Function of
YAP/TAZ
The simultaneous regulation of histone acetylation and total
histone occupancy strongly suggested the involvement of the
nucleosome remodeling and histone deacetylase (NuRD) com-
plex because this complex possesses both histone deacetylase
(HDAC) and chromatin-remodeling activity (Lai andWade, 2011).
In addition, the NuRD complex has been proposed to mediate
the repressor activity of the YAP/TAZ-TEAD-Smad3 complex
in human ES cells (Beyer et al., 2013). To test this possibility,
we first blocked NuRD activity by small inhibitory RNA (siRNA)-
mediated silencing of CHD4 (chromatin remodeling subunit) or
treatment with the HDAC inhibitor TSA (trichostatin A). These
treatments derepressed DDIT4 and Trail transcription in control
cells and restored their expression in YAP 5SA-expressing cells
(Figure 5A). Next, we examined whether YAP/TAZ recruit
the NuRD complex to target genes. Using ChIP-qPCR, we
confirmed that CHD4 enrichment at DDIT4 and Trail were
increased by YAP 5SA expression and reduced by YAP/TAZ
depletion (Figure 5B). MTA (metastasis associated) subunits
(MTA1/2/3) mediate NuRD complex targeting through direct pro-tein-protein interactions with transcription factors (Lai and
Wade, 2011). Co-immunoprecipitation experiments in 293T cells
showed that YAP can associate with all threeMTAproteins, most
strongly with MTA1 (Figure 5C). shRNA-mediated knockdown of
MTA1 in MCF10A cells increased DDIT4 and Trail mRNA levels
(Figure 5D). The relatively modest activation of DDIT4 and Trail
in MTA1 shRNA cells is likely attributable to compensation by
MTA2 and MTA3. These results indicate that YAP recruits the
NuRD complex via interaction with MTA subunits. To further
confirm the interaction between YAP and the NuRD complex,
we tested for any association at the endogenous level. To this
end, we examined three subunits of the NuRD complex (MTA1,
GATAD2A, and CHD4). When YAP was immunoprecipitated
from MCF10A cells, all three subunits were co-purified (Fig-
ure 5E). Reciprocally, YAP was co-purified in MTA1 immunopre-
cipitates (Figure 5F). As expected, the binding strength of YAP
was much weaker than that of the core NuRD components.
Given that TEAD is essential for the repression of YAP target
genes, we questioned whether TEAD might also be required
for the YAP-NuRD interaction. Flag-YAP 5SA readily co-purified
MTA1, GATAD2A, and CHD4, but the interactions with MTA1
and CHD4 were markedly reduced when Flag-YAP 5SA/S94A
was used for the immunoprecipitation (Figure 5G). Interestingly,
GATAD2A interacted with YAP 5SA and YAP 5SA/S94A to com-
parable degrees, suggesting that YAP-GATAD2A might form a
NuRD/TEAD-independent complex. Nonetheless, this result re-
inforces our conclusion that TEAD is required for the repression
of YAP target genes. Next, we asked whether Smad3 is required
for the repressor activity of YAP/TAZ. To address this, we gener-
ated MCF10A cells stably depleted of Smad3 (Figures S5A and
S5C). Even in a Smad3-depleted background, YAP 5SA was still
able to repress target genes (Figures S5A and S5B). Therefore,Cell Reports 11, 270–282, April 14, 2015 ª2015 The Authors 275
Figure 4. YAP Affects Histone Acetylation and Occupancy at DDIT4 and Trail Genes
(A) Pol2 ChIP-qPCR in YAP 5SA-expressing cells (first and second columns) or YAP/TAZ-depleted cells (third and fourth columns). Precipitated DNA was
analyzed by qPCR using primers amplifying the indicated regions relative to the TSS, normalized to the qPCR of input samples. Pol2 enrichment at the TSS in
control cells was adjusted to 100 (n = 4 for YAP 5SA expression experiments and n = 6 for YAP/TAZ siRNA experiments).
(B) Acetylated H3ChIP-qPCR normalized to total H3ChIP-qPCR. Precipitated DNAwas analyzed by qPCRusing primers amplifying the indicated regions relative
to the TSS. Acetylated H3 enrichment at each amplicon in control cells was adjusted to 1 (n = 4).
(C) Total H3 enrichment was quantified as in (A). H3 enrichment at each amplicon (positions are the same as in B) in control cells was adjusted to 1 (from left to
right, n = 4, n = 5, n = 5 and n = 4). Error bars indicate the SEM and the numbers above the bars indicate p values (paired Student’s t test).TGF-b-Smad3 is not an essential component of YAP/TAZ
repressor complexes at least for the analyzed target genes.
Repression of DDIT4 by YAP/TAZ Promotes mTORC1
Activity
Having established the repressor activity of YAP/TAZ, the next
important question was whether this contributes to the onco-
genic function of YAP/TAZ. Stress signals such as hypoxia,
DNA damage, and cell contact inhibition induce DDIT4. DDIT4
is well-established inhibitor of mTORC1 (mechanistic target of
rapamycin complex 1), which acts by increasing functional
pool of TSC1/2, key negative regulator of mTORC1 (DeYoung
et al., 2008). The kinase complex, mTORC1, plays a key role in
promoting cell growth and is often hyperactivated in cancers
(Zoncu et al., 2011). In line with the important role of mTORC1
in growth regulation, its activity is tightly controlled by nutrient
availability and growth factor signals. Signaling via growth fac-
tors or insulin activates the PI3K-Akt pathway, which in turn
inactivates TSC1/2 and PRAS40, the latter of which is another
negative regulator of mTORC1 (Inoki et al., 2002; Manning276 Cell Reports 11, 270–282, April 14, 2015 ª2015 The Authorset al., 2002; Potter et al., 2002; Vander Haar et al., 2007). Phos-
phatase and tensin homolog (PTEN) is a key inhibitor of Akt
signaling; it is one of the most frequently mutated genes in hu-
man cancer (Song et al., 2012), and the loss of PTEN hyperacti-
vates mTORC1 through Akt. In particular, hypoxia inhibits
mTORC1, which is absolutely dependent on DDIT4 induction
(Brugarolas et al., 2004). If repression of DDIT4 by YAP/TAZ is
important in maintaining mTORC1 activity, then cells with hyper-
active YAP should sustain mTORC1 activity in response to hyp-
oxia. Thus, we assessed mTORC1 activity by monitoring the
phosphorylation of two established substrates: S6K (S6 kinase)
and 4E-BP1 (4E binding protein 1). Induction of DDIT4 in
response to hypoxia was attenuated in YAP 5SA-expressing
cells (Figure 6A, bottom). As expected, mTORC1 activity was
readily abolished by hypoxia in control cells. In contrast,
mTORC1 activity was basally elevated in cells expressing YAP
5SA and was refractory to hypoxia (Figure 6A, upper). Introduc-
tion of DDIT4 into YAP 5SA-expressing MCF10A cells abol-
ished mTORC1 hyperactivity (Figure 6B). Depletion of YAP/
TAZdecreasedbasalmTORC1activity in control cells (Figure 6C,
Figure 5. The NuRD Complex Mediates Repression of DDIT4 and Trail by YAP/TAZ
(A) Control or YAP 5SA-expressingMCF10A cells were transfected with CHD4 siRNA for 2 days or treated with 1 mMTSA for 24 hr. mRNA levels of DDIT4 and Trail
were analyzed by qPCR. The numbers above the bars indicate the fold change between two samples. The western blot below confirms CHD4 depletion by
siCHD4. Error bars indicate the SEM (n = 3).
(B) Chd4 ChIP-qPCR in YAP 5SA-expressing cells (left) or YAP/TAZ-depleted cells (right) using primers amplifying indicated regions with respect to TSS. Error
bars indicate the SEM (n = 4 for YAP 5SA expression experiments and n = 6 for YAP/TAZ siRNA experiments), and the numbers above the bars indicate p values
(paired Student’s t test).
(C) 293T cells were transfected with HA-YAP and Flag-MTA1, Flag-MTA2, or Flag-MTA3. Nuclear lysates were enriched and immunoprecipitated with anti-Flag
antibody.
(D) MCF10A cells were transduced with shMTA1. mRNA levels of the indicated genes were analyzed by RT-qPCR. Error bars indicate the SEM (n = 4), and the
numbers above the bars indicate p values (paired Student’s t test).
(E) MCF10A nuclear lysates were immunoprecipitated with an anti-YAP antibody. Samples were analyzed by western blotting for the indicated proteins. An
asterisk (*) indicates a non-specific signal.
(F) MCF10A nuclear lysates were immunoprecipitated with an anti-MTA1 antibody. An asterisk (*) indicates a nonspecific signal.
(G) Lysates of MCF10A cells expressing Flag-YAP 5SA, Flag-YAP 5SA/S94A, or vector (control) were immunoprecipitated with an anti-Flag antibody.
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Figure 6. Repression of DDIT4 and Trail by YAP/TAZ Promotes mTORC1 Activity and Cell Survival
(A) Flag-YAP 5SA-expressing or control MCF10A cells were incubated in 1%O2 for 24 hr. Cell lysates were analyzed by western blotting for markers of mTORC1
activity. Below is the DDIT4 mRNA level normalized to b-actin transcripts in samples processed in parallel. Error bars indicate the SEM (n = 3), and the numbers
above the bars indicate p values (paired Student’s t test).
(B) Flag-YAP 5SA-expressing or control MCF10A cells were transduced with Flag-DDIT4 retrovirus and analyzed by western blotting.
(C) shDDIT4-transduced or control MCF10A cells were transfected with YAP/TAZ siRNAs and analyzed by western blotting.
(D) shTrail-transduced or control MCF10A cells were transfected with YAP/TAZ siRNAs. Cell death was examined by western blotting for cleaved caspase-3 and
PARP.
(E and F) Cells were treated as in (D), and TUNEL assays were performed. (E) Representative images of YAP/TAZ-depleted cells. Blue, DAPI; green, TUNEL-
positive cells. Scale bar represents 10 mm.
(F) Quantification of TUNEL-positive cells. At least 300 cells from five randomly selected fields were counted. Error bars indicate the SEM (n = 4), and the numbers
above the bars indicate p values (paired Student’s t test).lanes 1 and 2). Although mTORC1 activity was also reduced by
YAP/TAZ depletion in cells co-depleted of DDIT4, substantial
mTORC1 activity remained (Figure 6C, lanes 3 and 4). These re-
sults provide another novel mechanistic link between YAP/TAZ
and mTORC1 in addition to the previously reported YAP-
miR29-PTEN pathway (Tumaneng, 2012).
Repression of Trail by YAP/TAZ Promotes Cell Survival
Trail is a member of the TNF family of cytokines and has potent
cell-killing activity (Wang and El-Deiry, 2003). Trail was one of the
most strongly repressed targets of YAP (Figure 1). YAP/TAZ278 Cell Reports 11, 270–282, April 14, 2015 ª2015 The Authorsdepletion induced cell death, as indicated by increased cleavage
of caspase-3 and poly-(ADP-ribose) polymerase (PARP) (Fig-
ure 6D, lanes 1 and 2). Remarkably, shRNA-mediated knock-
down of Trail largely eliminated cell death induced by YAP/TAZ
depletion (Figure 6D, lanes 3 and 4). This result was also
confirmed by TUNEL (terminal deoxynucleotidyl transferase
dUTP nick-end labeling) assay (Figures 6E and 6F). This sug-
gests that cells depleted of YAP/TAZ die, at least in part, due
to Trail activity. Together with the DDIT4 data, these results
show that the repressor activity of YAP/TAZ contributes to cell
growth and survival.
Figure 7. Model Depicting Transcriptional Control by YAP/TAZ
See the Discussion for further details.The NuRD Complex Regulates mTORC1 and Cell
Survival through DDIT4 and Trail
Finally, we examined whether the NuRD complex also affects
mTORC1 activity and cell survival. Because TSA has many
nonspecific effects, we utilized an siRNA against CHD4. Our re-
sults revealed that CHD4 knockdown decreasedmTORC1 activ-
ity, as reflected by reduction of S6K phosphorylation, and that
this was partly restored by concomitant DDIT4 knockdown (Fig-
ure S6A). CHD4 knockdown also induced cell death, as reflected
by caspase-3 cleavage, and this was rescued by Trail knock-
down (Figure S6B). Importantly, CHD4 knockdown did not affect
either the abundance of YAP/TAZ or the phosphorylation of YAP
(Figure S6C), which is consistent with NuRD being downstream
of YAP/TAZ. CHD4 knockdown also decreased mTORC1 activ-
ity and induced cell death in YAP 5SA-expressing cells, although
this effect was less pronounced than that in control cells (Fig-
ure S6D). Thus, we speculate that YAP/TAZ may also regulate
mTORC1 activity and cell death via one or more DDIT4/Trail
independent mechanism(s). Indeed, YAP overexpression was
previously shown to confer resistance against diverse cell death
stimuli (Overholtzer et al., 2006), suggesting that YAP might
regulate downstream component of the apoptotic pathways.
DISCUSSION
In this study, we demonstrated a transcriptional co-repressor
function of YAP/TAZ, showing that YAP/TAZ repressed num-
erous genes, including those encoding tumor suppressors (Fig-
ure 1). Interestingly, the repressor function of YAP/TAZ required
TEAD transcription factors, which are also essential for YAP/TAZ
co-activator function (Figure 2). TEAD transcription factors have
been reported to be essential for the oncogenic properties of
YAP/TAZ, and our findings strengthen this concept. By investi-
gating epigenetic changes associated with gain or loss of YAP/
TAZ function, we found that the NuRD complex mediates the
repressor function of YAP/TAZ, at least in part (Figures 4 and
5). Using DDIT4 and Trail as examples, we showed that therepressor activity of YAP/TAZ contributes to their oncogenic
functions (Figure 6). Recent studies have shown that YAP-
TEAD recruits the NcoA6 H3K4 methyltransferase complex
and SWI/SNF chromatin-remodeling complex for target gene
activation (Oh et al., 2013, 2014; Qing et al., 2014; Skibinski
et al., 2014). Together with these studies, our results significantly
improve understanding of the transcriptional control exerted by
YAP/TAZ (Figure 7). An interesting topic for future studies would
be testing the relative contribution of co-activator and co-
repressor functions of YAP/TAZ in animal models.
Our study significantly expands on a previous report byWrana
and colleagues (Beyer et al., 2013). Most importantly, we gener-
alized the role of the YAP/TAZ-TEAD-NuRD complex in the regu-
lation of cell growth and survival, which is the major function of
YAP/TAZ (Figure 6). We also showed that the repressor complex
does not necessarily require Smad3 at least for the analyzed
genes (Figure S5). The interaction between YAP and Smad3 is
mediated by the WW domain and PY motif. Since the WW
domain was required for repression of a subset of target genes,
other PY motif-containing transcription factors, such as Egr-1
(early growth response 1), which interacts with YAP (Zagurov-
skaya et al., 2009), might contribute to YAP/TAZ function. Inter-
estingly, Trail is directly repressed by Egr-1 (Fu et al., 2003), and
Egr-1 can recruit the NuRD complex (Srinivasan et al., 2006).
Thus, YAP represses Trail expression together with another tran-
scription factor such as Egr-1, similar to the case of Smad3 in ES
cells. By default, the YAP/TAZ-TEAD complex is a transcriptional
activator because it can activate artificial reporters containing
tandem TEAD binding sites. Thus, it is reasonable to speculate
that another trans-acting factor (depicted as ‘‘X’’ in Figure 7),
which is specifically associated with repressed target genes,
converts YAP/TAZ-TEAD into a repressor. Our experiments
with Trail reporters underscore the importance of the genomic
landscape surrounding the TEAD binding motif for repression
of YAP target gene (Figure 3). Confirmation of this suppo-
sition awaits further characterization of the YAP/TAZ repressor
complex.Cell Reports 11, 270–282, April 14, 2015 ª2015 The Authors 279
In an effort to better understand the importance of YAP/TAZ
repressor activity in human cancers, we analyzed five published
datasets obtained frommicroarray analysis of breast cancer pa-
tients. However, two genes that are central to the present study,
DDIT4 and Trail, were not found to be correlated with YAP/TAZ
expression in the published datasets. This may reflect the het-
erogeneity of the biopsy samples or other factors associated
with cancer progression. For example, Trail is highly expressed
in immune cells, which infiltrate tumor tissues (Zauli and Sec-
chiero, 2006), while DDIT4 is highly induced by DNA damage
or hypoxia, which are associated with tumor growth (Brugarolas
et al., 2004; Ellisen et al., 2002). These factors might therefore
mask a correlation between YAP/TAZ and DDIT4/Trail expres-
sion. Nevertheless, our analysis of the genes in Table S1 re-
vealed that 12 genes showed recurrent inverse correlations
with YAP/TAZ expression in multiple datasets (Figure S7), sug-
gesting that the repressor function of YAP/TAZ may be relevant
to human breast cancers. Future work is warranted to perform
functional characterizations of these genes in tumorigenesis.
Although we mainly focused on two selected target genes in
the current study, many potentially interesting target genes are
repressed by YAP/TAZ. For example,ULK1 (unc-51 like auto-
phagy-activating kinase 1), a master activator of the autophagy
cascade (Mizushima, 2010), is repressed by YAP/TAZ. Thus,
YAP/TAZmight inhibit autophagy by transcriptionally downregu-
lating ULK1. We also found that many angiogenic genes were
repressed by YAP/TAZ (Figure 1). Although the biological signif-
icance of this is unclear, it is noteworthy that some stem cell
niches are considered to be hypoxic (Mohyeldin et al., 2010).
Such a hypoxic microenvironment could facilitate stem cell divi-
sion by promoting glycolytic metabolism. Therefore, YAP/TAZ in
stem cells might shape the niche by inhibiting local blood vessel
formation. Although a recent study found that YAP regulated
hypoxia-induced genes in the opposite direction (Ma et al.,
2015), the hypoxia-induced genes we have examined so far
(DDIT4, VEGFA, and CA12) were all repressed by YAP 5SA
and increased by YAP/TAZ siRNA, even under hypoxic condi-
tions (data not shown). This difference might reflect the use of
different cell lines, as the authors of the prior study used the
metastatic breast cancer cell line, MDA-MB-231.
In addition, many previously reported phenotypes of Hippo-
pathway-mutant mice might be explained in light of a repressor
function. For example, Yap-deficient cholangiocytes undergo
spontaneous cell death (Zhang et al., 2010), and Yap-deficient
mammary glands fail to proliferate and undergo cell death
following pregnancy (Chen et al., 2014). Yet, no identified target
genes of Yap are capable of accounting for these phenotypes.
Our findings suggest that the failure to repress certain cytostatic
or cell-death-inducing genes might cause such phenotypes.
Going forward, it will be necessary to include a consideration
of repressed targets to fully understand the role of YAP/TAZ in
stem cell biology and cancer.EXPERIMENTAL PROCEDURES
Cell Culture
MCF10A, AML12, RPE, and 293T cells were purchased from American
Type Culture Collection. MCF10A cells were cultured in Dulbecco’s modified280 Cell Reports 11, 270–282, April 14, 2015 ª2015 The AuthorsEagle medium (DMEM)/F12 supplemented with 5% horse serum (Invitrogen),
20-ng/ml epidermal growth factor (EGF; Peptrotech), 10-mg/ml insulin (Sigma),
0.5-mg/ml hydrocortisone (Sigma), 100-ng/ml cholera toxin (Sigma), and peni-
cillin/streptomycin (Invitrogen). 293T cells were cultured in DMEM supple-
mented with 10% fetal bovine serum (FBS) and penicillin/streptomycin.
AML12 cells were cultured in DMEM/F12 supplemented with 10% FBS,
0.005-mg/ml insulin-transferrin-selenium (Invitrogen), 40-ng/ml dexametha-
sone (Sigma), and penicillin/streptomycin. RPE cells were cultured in
DMEM/F12 supplemented with 10% FBS and penicillin/streptomycin. Sav1/
p53 double knockout (dKO) cells, a kind gift fromDr. Johnson (M.D. Anderson),
were cultured in DMEM supplemented with 10% FBS and 2-mM glutamine
(Invitrogen).
Microarray Analysis
RNA was collected and analyzed using a Human HT-12v4 expression chip
(Illumina). All expression values (in log2) were normalized and statistically
analyzed to identify genes that were significantly upregulated or downregu-
lated by 4-OHT in MCF-10A ERT2-YAP 2SA cells (p < 0.001) without being
significantly changed in control MCF-10A ERT2 cells. Heat maps for gene
sets of interest were generated using Multi-experiment Viewer (MeV). Raw mi-
croarray analysis data are available in Gene Expression Omnibus (GEO:
GSE60579).
siRNA Transfection
siRNAs were synthesized by Samchully Pharm. siRNA duplexes at a concen-
tration of 20 mM were prepared by annealing single-stranded oligonucleo-
tides. For transfection, Lipofectamine RNAi Max reagent (Invitrogen) was
used following the manufacturer’s instructions. Analyses were performed
2 days after transfection. Targeting sequences for siRNAs are presented in
Table S3.
Statistical Analysis
Graphs were drawn using GraphPad Prism software. Statistical analyses were
performed using paired two-tailed Student’s t test with a 95% CI.
For further details regarding the materials and methods used in this study,
see Supplemental Experimental Procedures.
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The accession number for the microarray data reported in this paper is GEO:
GSE60579.
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